浏览全部资源
扫码关注微信
环磷酰胺静脉冲击联合糖皮质激素治疗特发性膜性肾病的疗效及安全性研究
Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy
- 第三军医大学学报 2021年43卷第12期 页码：1173-1178
- 作者机构：
1.510515 广州 南方医科大学第二临床医学院
2.510000 广州, 广东省人民医院(广东省医学科学院)肾内科
3.515063 广东 汕头, 汕头大学医学院
- 作者简介：
[叶智明，E-mail: yezhiming@gdph.org.cn YE Zhiming, E-mail: yezhiming@gdph.org.cn
- 基金信息：
DOI：10.16016/j.1000-5404.202012213
中图分类号： R451;R692;R969.4收稿：2020-12-26，
修回：2021-02-06，
纸质出版：2021-06-30
- 稿件说明：
移动端阅览
谢新富, 谢冰莹, 郑全, 等. 环磷酰胺静脉冲击联合糖皮质激素治疗特发性膜性肾病的疗效及安全性研究[J]. 第三军医大学学报, 2021,43(12):1173-1178.
Xinfu XIE, Bingying XIE, Quan ZHENG, et al. Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy[J]. Journal of Third Military Medical University, 2021, 43(12): 1173-1178.
谢新富, 谢冰莹, 郑全, 等. 环磷酰胺静脉冲击联合糖皮质激素治疗特发性膜性肾病的疗效及安全性研究[J]. 第三军医大学学报, 2021,43(12):1173-1178. DOI： 10.16016/j.1000-5404.202012213.
Xinfu XIE, Bingying XIE, Quan ZHENG, et al. Efficacy and safety of high-dose cyclophosphamide intravenous boost combined with glucocorticoid in treatment of idiopathic membranous nephropathy[J]. Journal of Third Military Medical University, 2021, 43(12): 1173-1178. DOI： 10.16016/j.1000-5404.202012213.
摘要
目的
2
评价环磷酰胺(cyclophosphamide
CTX)静脉冲击联合糖皮质激素在治疗特发性膜性肾病(idiopathic membranous nephropathy，IMN)治疗中的有效性和安全性。
方法
2
回顾性分析78例临床表现为肾病综合征(nephrotic syndrome
NS)的IMN患者临床资料。治疗组: 静脉滴注CTX联合糖皮质激素组39例；对照组: 口服CTX联合糖皮质激素组39例。比较两组患者治疗前及治疗后3、6、12个月的蛋白尿缓解、血清白蛋白、估算肾小球滤过率(estimated glomerular filtration rate，eGFR)变化、复发率及不良反应发生情况。
结果
2
ICTX组在3、6、12个月的蛋白尿总缓解率高于OCTX组，分别为50.0%
vs
46.4%，59.4%
vs
50.0%，88.9%
vs
75%，但差异无统计学意义。两组患者在治疗3、6、12个月后血清白蛋白(sALB)、eGFR较基线值均明显升高，治疗3个月时，ICTX组sALB升高更显著(6.2
vs
4.8 g/L，
P
=0.013)。两组治疗后24 h尿蛋白(24 h UP)、血清肌酐(Scr)基线值均明显下降(
P
<
0.05)。在完全缓解(complete remission，CR)或部分缓解(partial remission，PR)后，ICTX组和OCTX组复发率分别为8.3%和13%，但差异无统计学意义。治疗3个月时，ICTX组血WBC较OCTX组高。ICTX组共发生9例(23.1%)不良反应，而OCTX组为10例(25.6%)。
结论
2
ICTX组方案可显著降低临床表现为NS的IMN患者尿蛋白，提高蛋白尿缓解率，且治疗结束后复发率低，同时可更快速升高血清白蛋白，耐受性好，不良反应无明显增加。
Abstract
Objective
2
To evaluate the efficacy and safety of high-dose cyclophosphamide (CTX) intravenous injection combined with glucocorticoid in the treatment of idiopathic membranous nephropathy (IMN).
Methods
2
Clinical data of 78 IMN patients with manifestation of nephrotic syndrome (NS) admitted in Guangdong Provincial People's Hospital from January 2007 to June 2019 were collected and retrospectively analyzed. The patients were assigned into either intravenous CTX combined with glucocorticoid group (ICTX group
n=39)
or oral CTX combined with glucocorticoid group (OCTX group
n=39). The subjects of ICTX group were treated with monthly intravenous CTX administration 0.50~0.75 g/m
2
+oral prednisone 0.5 mg/(kg·d) for 6 months. By contrast
those in OCTX group were given intravenous methylprednisolone 0.5 g qd×3 d+oral prednisone 0.5 mg/(kg·d)×27 d in the firs
t
third and fifth month
respectively
and given oral CTX 2.5mg/(kg·d)+ oral prednisone 10 mg/d in the second
fourth and sixth month
respectively. Comparison was made between the 2 groups about the remission of proteinuria
serum albumin (sALB)
estimated glomerular filtration rate (eGFR)
recurrence rate and incidence of adverse reactions (ADR) before and 3
6 and 12 months after the treatment.
Results
2
The total remission rate of proteinuria in ICTX group was higher than that in OCTX group at 3
6
12 months (50.0%
vs
46.4%; 59.4%
vs
50.0%; 88.9%
vs
75.0%
respectively)
though showed no significant differences. sALB and eGFR in both groups were significantly increased from baseline
while 24 h urinary protein (24hUP) and serum creatinine (Scr) were decreased in 3
6
12 months after the treatment (
P
<
0.05); and sALB had a more significant rise in ICTX group than OCTX group at 3 months (6.2
vs
4.8 g/L
P
=0.013). After complete remission (CR) or partial remission (PR)
the recurrence rates of ICTX and OCTX groups represented 8.3% and 13.0%
respectively
with no significant differences. In addition
the WBC count in the ICTX group was higher than that in the OCTX group at 3 months. Finally
a total of 9 cases of ADR occurred in the ICTX group (23.1%) and 10 cases in the OCTX group (25.6%).
Conclusion
2
The ICTX regimen significantly reduces proteinuria of IMN patients with clinical manifestation of NS
improving the remission rate of proteinuria
increasing serum albumin rapidly
and showing a low recurrence rate
good tolerance
as well as no significant increase in adverse reactions.
关键词
Keywords
references
BOMBACK A S, FERVENZA F C. Membranous nephropathy: approaches to treatment[J]. Am J Nephrol, 2018, 47(Suppl 1): 30-42. DOI: 10.1159/000481635.
GUO W, ZHANG Y, GAO C, et al . Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody[J ] . Peer J, 2020, 8: e8650. DOI: 10.7717/peerj.8650.
DAHAN K, DEBIEC H, PLAISIER E, et al . Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up[J ] . J Am Soc Nephrol, 2017, 28(1): 348-358. DOI: 10.1681/asn.2016040449.
胡晓帆, 徐静, 陈楠. 利妥昔单抗治疗特发性膜性肾病的进展[J]. 中华内科杂志, 2016, 55(7): 558-560.
HU X F, XU J, CHEN N. Progress of rituximab in the treatment of idiopathic membranous nephropathy[J]. Chin J Intern Med, 2016, 55(7): 558-560.
XU X, WANG G, CHEN N, et al . Long-term exposure to air pollution and increased risk of membranous nephropathy in China[J ] . J Am Soc Nephrol, 2016, 27(12): 3739-3746. DOI: 10.1681/asn.2016010093.
Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care[J]. Lancet 2015; 385(9981): 1983-1992. DOI: 10.1016/S0140-6736(15)60731-0.
NIKOLOPOULOU A, CONDON M, TURNER-STOKES T, et al . Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial[J ] . BMC Nephrol, 2019, 20(1): 352. DOI: 10.1186/s12882-019-1539-z.
KERI K C, BLUMENTHAL S, KULKARNI V, et al . Primary membranous nephropathy: comprehensive review and historical perspective[J ] . Postgrad Med J, 2019, 95(1119): 23-31. DOI: 10.1136/postgradmedj-2018-135729.
Group KDIGO. KDIGO clinical practice guideline for glomerulonephritis[J]. Kidney Int Suppl. 2012;2(2): 186-197.
LIANG Q, LI H, XIE X, et al . The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy[J ] . Ren Fail, 2017, 39(1): 512-518. DOI: 10.1080/0886022x.2017.1325371.
JHA V, GANGULI A, SAHA T K, et al . A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy[J ] . J Am Soc Nephrol , 2007, 18(6): 1899-1904. DOI: 10.1681/asn.2007020166.
HOWMAN A, CHAPMAN T L, LANGDON M M, et al . Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial[J ] . Lancet, 2013, 381(9868): 744-751. DOI: 10.1016/s0140-6736(12)61566-9.
VAN DE LOGT A E, HOFSTRA J M, WETZELS J F. Pharmacological treatment of primary membranous nephropathy in 2016[J]. Expert Rev Clin Pharmacol, 2016, 9(11): 1463-1478. DOI: 10.1080/17512433.2016.1225497.
FLOEGE J, BARBOUR S J, CATTRAN D C, et al . Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J ] . Kidney Int, 2019, 95(2): 268-280. DOI: 10.1016/j.kint.2018.10.018.
PONTICELLI C, ZUCCHELLI P, IMBASCIATI E, et al . Controlled trial of monthly alternated courses of steroid and chlorambucil for idiopathic membranous nephropathy[J ] . Proc Eur Dial Transpl Assoc Eur Dial Transpl Assoc, 1983, 19: 717-723.
REN S, WANG Y, WANG Y, et al . Comparative effectiveness and tolerance of immunosuppressive treatm ents for idiopathic membranous nephropathy: a network meta-analysis[J ] . PLoS ONE, 2017, 12(9): e0184398. DOI: 10.1371/journal.pone.0184398.
LI Y C, HUANG J, LI X, et al . A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: a meta-analysis[J ] . Nefrologia, 2019, 39(3): 269-276. DOI: 10.1016/j.nefro.2018.10.008.
POZDZIK A, BROCHÉRIOU I, DAVID C, et al . Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management[J ] . Biomed Res Int, 2018, 2018: 6281054. DOI: 10.1155/2018/6281054.
Mathrani V, Alejmi A, Griffin S, et al . Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy[J ] . Clin Kidney J. 2017;10(4): 450-454. DOI: 10.1093/ckj/sfw152.
RAMACHANDRAN R, HN H K, KUMAR V, et al . Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial[J ] . Nephrology (Carlton), 2016, 21(2): 139-146. DOI: 10.1111/nep.12569.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
